OKUR (OnKure Therapeutics) Net Debt Paydown Yield % : 0.97% (As of Jul. 18, 2026) — 54% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OKUR OnKure Therapeutics Inc OKUR
14 GF Score
Price $4.20
! 1 Warning Sign
View Full Analysis

What is OnKure Therapeutics Net Debt Paydown Yield %?

OnKure Therapeutics OKUR +2.44% 14 Net Debt Paydown Yield % is 0.97% as of Jul. 18, 2026, which is 54% below its 10-year median of 2.12. GuruFocus rates OKUR with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,161 Biotechnology companies, OnKure Therapeutics ranks better than 73.3% on this metric.

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, OnKure Therapeutics's Net Debt Paydown Yield % was 0.97%.


OnKure Therapeutics  (NAS:OKUR) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


OnKure Therapeutics Net Debt Paydown Yield % Related Terms


OnKure Therapeutics Net Debt Paydown Yield % Historical Data

* Premium members only.

The historical data trend for OnKure Therapeutics's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OnKure Therapeutics Net Debt Paydown Yield % Chart

OnKure Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Debt Paydown Yield %
0.00 0.00 -1.33 3.65

OnKure Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.83 5.24 3.25 3.65 0.98

OKUR vs ANTX, PLX, KRRO: Net Debt Paydown Yield % Comparison

For the Biotechnology subindustry, OnKure Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OnKure Therapeutics Net Debt Paydown Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where OnKure Therapeutics's Net Debt Paydown Yield % falls into.


OKUR
14GF Score
OnKure Therapeutics Inc OKUR
Net Debt Paydown Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OnKure Therapeutics Net Debt Paydown Yield % Calculation

OnKure Therapeutics's Net Debt Paydown Yield % for the quarter that ended in Mar. 2026 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 2.28-0.62 )/170.07948
=0.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

What does a Net Debt Paydown Yield % of 0.97% mean?
OnKure Therapeutics (OKUR) has a Net Debt Paydown Yield % of 0.97% as of Jul. 18, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on OnKure Therapeutics and its competitors. This is 54% below median its historical median of 2.12. According to the industry distribution chart, OnKure Therapeutics ranks #310 out of 1161 companies in the Biotechnology industry, placing it in the top 26.7%.
Is OnKure Therapeutics' Net Debt Paydown Yield % too high?
OnKure Therapeutics' current Net Debt Paydown Yield % of 0.97% is 54% below median its 10-year median of 2.12. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. OnKure Therapeutics' value of 0.97% is 3133.3% above this industry median. Based on the distribution chart, OnKure Therapeutics ranks #310 out of 1161 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OnKure Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does OnKure Therapeutics' Net Debt Paydown Yield % compare to ANTX and PLX?
According to the Biotechnology industry distribution chart, OnKure Therapeutics ranks #310 out of 1161 companies for Net Debt Paydown Yield %. This puts OnKure Therapeutics in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.03. OnKure Therapeutics' value of 0.97% is 3133.3% above this benchmark. While the company's 10-year median is 2.12 vs. the industry median of 0.03, OnKure Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OnKure Therapeutics's current Net Debt Paydown Yield % of 0.97% is 3133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on OnKure Therapeutics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OnKure Therapeutics's current Net Debt Paydown Yield % is 0.97%, which is 54% below median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OnKure Therapeutics stock overvalued right now?
OnKure Therapeutics (OKUR) has a current Net Debt Paydown Yield % of 0.97%. The current Net Debt Paydown Yield % is 0.97%, which is 54% below median its 10-year median of 2.12 and 3133.3% above the Biotechnology industry median of 0.03. OnKure Therapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For OnKure Therapeutics (OKUR), the current Net Debt Paydown Yield % is 0.97% as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OnKure Therapeutics Business Description

Address 6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3K?. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
14GF Score

Get the complete analysis for OKUR

Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.20
Price